Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Pharmaceutical Companies
  4. AnaptysBio
Thumbnail
November 12, 2021

Astra presses on with bispecifics

Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.

Thumbnail
September 27, 2021

Oncology the focus for big pharma catalysts

The fourth quarter will see key immunotherapy data from Astrazeneca and Merck, while full details on Glaxo's anaemia pill, daprodustat, are expected.

Article image
Vantage logo
September 17, 2021

Esmo 2021 – Keytruda challenges Jemperli and adjuvant melanoma

Glaxo’s anti-PD-1 MAb might not have a market niche to itself for long, while a separate trial could help Keytruda double its adjuvant melanoma potential.

Article image
Vantage logo
September 01, 2021

US FDA approval tracker: August

Article image
Vantage logo
July 21, 2021

Not yet time for Tim-3

Article image
Vantage logo
April 23, 2021

Jemperli arrives just as accelerated approvals face a grilling

Article image
Vantage logo
March 08, 2021

Anaptysbio fails to excite ahead of pivotal push

Article image
Vantage logo
January 26, 2021

Novartis goes up against Glaxo in Tim-3

Article image
Vantage logo
January 20, 2021

2020 drug approvals rise despite Covid-19

Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.

Article image
Vantage logo
January 20, 2021

Glaxo joins the Covid-19 delay queue

Article image
Vantage logo
October 29, 2020

Glaxo’s latest asthma cull puts Astra in the spotlight

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.